Michael Rosenberg, MD
Interventional Cardiology · Manitowoc, WINPI 1356385330
Payments from drug & device makers
Across 473 payments — averaging $429.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$88K
- Sanofi US Services Inc.$30K
- Regeneron$27K
- Bayer$15K
- Novartis$14K
- CSL Behring$13K
- plus $17K from 35 others
What the payments were for
- Consulting fees$9,0918%
- Speaking & faculty fees$80,30072%
- Travel & lodging$10,89410%
- Food & beverage$11,04310%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 116 | $87,563 |
| Sanofi US Services Inc. | 11 | $30,408 |
| Regeneron | 26 | $27,033 |
| Bayer | 8 | $14,536 |
| Novartis | 50 | $13,782 |
| CSL Behring | 15 | $13,365 |
| AstraZeneca | 37 | $3,947 |
| Penumbra, Inc. | 7 | $2,153 |
| Pfizer | 20 | $2,151 |
| E.r. Squibb & Sons, L.L.C. | 41 | $903 |
| Biotronik Inc. | 6 | $856 |
| Angiodynamics, Inc. | 3 | $852 |
| Inari Medical, Inc. | 8 | $817 |
| Abbott | 10 | $752 |
| Recor Medical Inc | 23 | $678 |
| BD | 2 | $414 |
| GE HealthCare | 1 | $398 |
| ZOLL Medical Corporation | 1 | $380 |
| Amgen | 15 | $338 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $260 |
| Boston Scientific | 7 | $232 |
| Heartflow, Inc. | 10 | $226 |
| Novo Nordisk | 8 | $201 |
| Shockwave Medical, Inc | 1 | $149 |
| Abiomed | 5 | $123 |
| Cook Medical LLC | 2 | $119 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| Lexicon Pharmaceuticals, Inc. | 5 | $99 |
| Janssen Scientific Affairs, LLC | 3 | $73 |
| Chiesi USA, Inc. | 3 | $58 |
| Cardiovascular Systems Inc. | 4 | $56 |
| Merck | 3 | $54 |
| Bard Peripheral Vascular, Inc. | 3 | $51 |
| Medtronic | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Philips North America LLC | 1 | $33 |
| Veryan Medical Incorporated | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Corcept Therapeutics | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$85,980
- PRALUENT$8,708
- Indigo System$2,041
- VYNDAQEL$1,800
- Auryon Laser System 100-120 Vac$852
- FLOWTRIEVER CATHETER, S$632
- CT THROMBECTOMY SYSTEM KIT$632
- MUSE$398
- Defibrillator$380
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$283
- FARXIGA$220
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$173
- TrapIT$164
- NHancer Rx$164
- Orsiro Mission$164
- PK Papyrus$164
- ReCross$164
- MitraClip$154
- Vascular Lithotripsy$149
- PARADISE RENAL DENERVATION SYSTEM$133
How this compares
$203,343 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 195 | $194,106 |
| EntrestoSacubitril/Valsartan | 123 | $191,405 |
| EliquisApixaban | 136 | $138,908 |
| BrilintaTicagrelor | 141 | $127,812 |
| JardianceEmpagliflozin | 84 | $100,602 |
| FarxigaDapagliflozin Propanediol | 73 | $70,602 |
| Repatha SureclickEvolocumab | 24 | $26,199 |
| DapagliflozinDapagliflozin Propanediol | 11 | $8,854 |
| Metoprolol Succinate | 394 | $5,126 |
| ClopidogrelClopidogrel Bisulfate | 427 | $4,853 |
| Rosuvastatin Calcium | 308 | $4,399 |
| Atorvastatin Calcium | 289 | $3,136 |
| Losartan Potassium | 243 | $2,229 |
| Ranolazine ErRanolazine | 19 | $1,811 |
| Digoxin | 49 | $1,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $3,947 | $198,414214 claims |
| Johnson & JohnsonXarelto | $87,563 | $194,106195 claims |
| NovartisEntresto | $13,782 | $191,405123 claims |
| PfizerEliquis | $2,151 | $138,908136 claims |
| Boehringer IngelheimJardiance | $20 | $100,60284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Manitowoc
- Matthew GentileManitowoc$30K
- Tanvir BajwaMilwaukee$3M
- Suhail AllaqabandMilwaukee$1.5M
- Amish RavalMadison$921K
- German LarrainWausau$820K
- Simil GalaGreen Bay$588K
- Michael SalingerMilwaukee$356K
- Kurt JacobsonMadison$226K
- Arun KalyanasundaramMarshfield$201K
- Michael CinquegraniMilwaukee$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.